



EMPOWERING *patent* OWNERS, REWARDING INVENTION

Contact:

Rob Stewart
Tel 1+ (949) 480-8311
rs@acaciares.com

FOR RELEASE

June 6, 2017

ACACIA SUBSIDIARY ENTERS INTO LICENSE AGREEMENT WITH MEDTRONIC, INC.

Newport Beach, Calif. – (BUSINESS WIRE) June 06, 2017 – [Acacia Research Corporation](#) (NASDAQ: ACTG) announced today that Acacia Research Group LLC and its LifePort Sciences LLC subsidiary have entered into a license agreement with Medtronic, Inc. and Medtronic Vascular Inc. covering patents relating to surgical devices. The agreement resolves litigation that was pending in the United States District Court for the District of Delaware.

ABOUT ACACIA RESEARCH CORPORATION

Founded in 1993, [Acacia Research Corporation](#) (NASDAQ: ACTG) is the industry leader in patent licensing. An intermediary in the patent marketplace, Acacia partners with inventors and patent owners to unlock the financial value in their patented inventions. Acacia bridges the gap between invention and application, facilitating efficiency and delivering monetary rewards to the patent owner.

For more information, visit: www.acaciaresearch.com

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.